GlobalData on MSN4mon
Amneal files again for FDA approval of first dihydroergotamine autoinjector
Amneal Pharmaceuticals has submitted another new drug application (NDA) for its dihydroergotamine (DHE) prefilled syringe ...
Seeking Alpha1mon
Amneal projects $3B-$3.1B revenue in 2025 with biosimilars and CREXONT as key drivers
Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four times, and notable ...
Benzinga.com1mon
Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars
Amneal reported Q4 sales of $730.52M, up 18% Y/Y, beating estimates, while adjusted EPS of $0.12 missed the $0.15 consensus. 2025 guidance: Revenue of $3B-$3.1B, adjusted EPS of $0.65-$0.70, and ...